Logo image of ALKS

ALKERMES PLC (ALKS) Stock Price, Quote, News and Overview

NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD

27  -0.2 (-0.74%)

After market: 27 0 (0%)

ALKS Quote, Performance and Key Statistics

ALKERMES PLC

NASDAQ:ALKS (4/17/2025, 8:01:38 PM)

After market: 27 0 (0%)

27

-0.2 (-0.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High36.45
52 Week Low22.9
Market Cap4.45B
Shares164.84M
Float161.50M
Yearly DividendN/A
Dividend YieldN/A
PE9.31
Fwd PE14.4
Earnings (Next)05-01 2025-05-01/bmo
IPO07-16 1991-07-16


ALKS short term performance overview.The bars show the price performance of ALKS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20

ALKS long term performance overview.The bars show the price performance of ALKS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10

The current stock price of ALKS is 27 USD. In the past month the price decreased by -20.4%. In the past year, price increased by 13.21%.

ALKERMES PLC / ALKS Daily stock chart

ALKS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.40B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.89B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About ALKS

Company Profile

ALKS logo image Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.

Company Info

ALKERMES PLC

Connaught House, 1 Burlington Road, Dublin 4

DUBLIN DUBLIN DUBLIN 4 IE

CEO: Richard F. Pops

Employees: 2100

Company Website: https://www.alkermes.com/

Investor Relations: https://investor.alkermes.com

Phone: 35317728000

ALKERMES PLC / ALKS FAQ

What is the stock price of ALKERMES PLC today?

The current stock price of ALKS is 27 USD. The price decreased by -0.74% in the last trading session.


What is the ticker symbol for ALKERMES PLC stock?

The exchange symbol of ALKERMES PLC is ALKS and it is listed on the Nasdaq exchange.


On which exchange is ALKS stock listed?

ALKS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALKERMES PLC stock?

22 analysts have analysed ALKS and the average price target is 40.36 USD. This implies a price increase of 49.49% is expected in the next year compared to the current price of 27. Check the ALKERMES PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALKERMES PLC worth?

ALKERMES PLC (ALKS) has a market capitalization of 4.45B USD. This makes ALKS a Mid Cap stock.


How many employees does ALKERMES PLC have?

ALKERMES PLC (ALKS) currently has 2100 employees.


What are the support and resistance levels for ALKERMES PLC (ALKS) stock?

ALKERMES PLC (ALKS) has a support level at 26.68 and a resistance level at 33.8. Check the full technical report for a detailed analysis of ALKS support and resistance levels.


Is ALKERMES PLC (ALKS) expected to grow?

The Revenue of ALKERMES PLC (ALKS) is expected to decline by -7.75% in the next year. Check the estimates tab for more information on the ALKS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALKERMES PLC (ALKS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALKERMES PLC (ALKS) stock pay dividends?

ALKS does not pay a dividend.


When does ALKERMES PLC (ALKS) report earnings?

ALKERMES PLC (ALKS) will report earnings on 2025-05-01, before the market open.


What is the Price/Earnings (PE) ratio of ALKERMES PLC (ALKS)?

The PE ratio for ALKERMES PLC (ALKS) is 9.31. This is based on the reported non-GAAP earnings per share of 2.9 and the current share price of 27 USD. Check the full fundamental report for a full analysis of the valuation metrics for ALKS.


What is the Short Interest ratio of ALKERMES PLC (ALKS) stock?

The outstanding short interest for ALKERMES PLC (ALKS) is 8.82% of its float. Check the ownership tab for more information on the ALKS short interest.


ALKS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 75.69% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALKS Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ALKS. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALKS Financial Highlights

Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 104.23% compared to the year before.


Industry RankSector Rank
PM (TTM) 23.57%
ROA 17.86%
ROE 25.06%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%377.27%
Sales Q2Q%13.91%
EPS 1Y (TTM)104.23%
Revenue 1Y (TTM)-6.36%

ALKS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to ALKS. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of -35.34% and a revenue growth -7.75% for ALKS


Ownership
Inst Owners105.48%
Ins Owners1.62%
Short Float %8.82%
Short Ratio8.21
Analysts
Analysts78.18
Price Target40.36 (49.48%)
EPS Next Y-35.34%
Revenue Next Year-7.75%